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DObjective: Atrial fibrosis is related to atrial fibrillation but may differ in patients with mitral valve disease or
lone atrial fibrillation. Therefore, we studied atrial fibrosis in patients with atrial fibrillationþmitral valve dis-
ease or with lone atrial fibrillation and compared it with controls.
Methods: Left and right atrial appendages amputated duringMaze III surgery for lone atrial fibrillation (n¼ 85)
or atrial fibrillationþmitral valve disease (n ¼ 26) were embedded in paraffin, sectioned, and stained with pic-
rosirius red. Atria from 10 deceased patients without a cardiovascular history served as controls. A total of 1048
images (4-mm sections, 10-fold magnification, 4 images per appendage) were obtained and digitized. The per-
centage of fibrous tissue was calculated by quantitative morphometry.
Results: Irrespective of the presence or absence of atrial fibrillation or mitral valve disease, more fibrous tissue
was present in right atrial appendages than in left atrial appendages (12.7%  5.7% vs 8.2%  3.9%;
P<.0001). The mean amount of fibrous tissue in the atria was significantly larger in patients with atrial fibril-
lationþmitral valve disease than in patients with lone AF and controls (13.6%  5.8%, 9.7%  3.2%, and
8.8%  2.4%, respectively; P<.01). No significant differences existed between patients with lone atrial fibril-
lation and patients without a cardiovascular history (controls).
Conclusions: Atria of patients with atrial fibrillation and mitral valve disease have more fibrosis than atria of
patients with lone atrial fibrillation. However, patients with lone atrial fibrillation have an equal amount of atrial
fibrosis compared with controls. These findings support the notion that fibrosis plays a more important role in the
pathogenesis of atrial fibrillation secondary to mitral valve disease than in lone atrial fibrillation and potentially
explains the relatively poor success of antiarrhythmic surgery in patients with mitral valve disease. (J Thorac
Cardiovasc Surg 2012;144:327-33)Atrial fibrillation (AF) is the most common sustained ar-
rhythmia in humans and has an increased prevalence in el-
derly patients and patients with mitral valve disease
(MVD), heart failure, hypertension, or pulmonary disease.1
Both electrical and structural remodeling of the atria play
an important role in the pathogenesis of AF.2 Experimental
and clinical investigations have shown a relation between
atrial interstitial fibrosis and AF with or without structural
heart diseases.3-5 Fibrosis resulting from chronic atrial
dilatation and stretch may cause AF,6 whereas AF itself
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The Journal of Thoracic and CaThe amount of fibrous tissue probably affects the success of
nonmedical therapy directed at AF suppression and preven-
tion, such as Maze(-like) surgery. Although surgery di-
rected against AF can be effective in the treatment of lone
AF, it is less effective in the treatment of AF secondary to
MVD.7
Organized lines of fibrotic scar tissue created by
Maze(-like) surgery prevents AF by reducing the tissue
mass that could sustain reentry. Diffuse interstitial fibrosis
also reduces the electrical tissue mass but facilitates reentry
arrhythmias via 2 mechanisms. First, it forms barriers of
nonconductive tissue that can lead to longer activation paths
(‘‘zigzag’’ conduction) with mainly transversal conduction
slowing and thus increased anisotropic conduction, which
is associated with reentry.8,9 The ‘‘zigzag’’ conduction
locally prolongs atrial activation time and thereby shortens
the dimension of a potential reentrant activation path.
Second, these barriers create geometric variation within
the myocardium and cause sites of sudden myocardial
expansion that can lead to current-to-load mismatch.10
Both mechanisms promote the occurrence of unidirectional
conduction block, which is a prerequisite for the initiation
and persistence of reentry arrhythmias, such as AF.rdiovascular Surgery c Volume 144, Number 2 327
Abbreviations and Acronyms
AF ¼ atrial fibrillation
ASD ¼ atrial septal defect
LAA ¼ left atrial appendage
MVD ¼ mitral valve disease
RAA ¼ right atrial appendage
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C
DBecause AF is associated with MVD and more difficult
to treat than lone AF,1,7 we hypothesized that atria of
patients with AF and MVD contain more diffuse fibrotic
tissue than atria of patients with lone AF. Furthermore,
comparison of the fibrous tissue content in atria of
patients with lone AF with that of control patients
without a history of AF may elucidate fibrosis secondary
to AF. A secondary study objective was the assessment
of predictors for the amount of fibrous tissue in the atria.
We therefore analyzed left atrial appendages (LAAs)
and right atrial appendages (RAAs) and collected
clinical data of patients who had undergone surgery for
AF with or without mitral valve surgery. Postmortem
tissues for control were obtained from patients without a
cardiovascular history.FIGURE 1. Picrosirius red staining of a 4-mM section from the LAA at
103 magnification. Fibrous tissue is stained red, and (atrial) myocardium
is stained yellow-orange. Background, perivascular, endocardial fibrosis,
and epicardial fibrosis are excluded from quantification (grey areas).MATERIALS AND METHODS
Study Population
All tissue samples were obtained at the St Antonius Hospital, Nieuwe-
gein, The Netherlands. The study was in accordancewith the declaration of
Helsinki and approved by the institutional review board. The study con-
formed to our local institutional protocol, which describes the use of human
tissues for research. Data were anonymously and retrospectively collected.
In accordance with our local protocol, no informed consent was necessary
because the tissue samples were resected as part of standard therapy or
diagnosis.
LAAs and RAAs were routinely removed during elective classic Maze
III surgery without (lone AF) or with mitral valvuloplasty or mitral valve
replacement (AFþMVD). The lone AF group consisted of 85 patients
who had undergone a classic Maze III procedure only and included 6 pa-
tients with a small type II atrial septal defect (ASD). These ASDs were per-
operatively detected by coincidence, could be closed without a patch, were
not visible on echocardiography peroperatively, and were therefore consid-
ered to have no significant hemodynamic consequences. All other ASDs
(type I or II) were excluded. The group with AF and mitral valve surgery
comprised 26 patients. Inclusion criteria for Maze III surgery have been de-
scribed in detail.11
Patients without a cardiac history served as controls. Tissue samples
for the control group were obtained from hearts of 10 deceased patients
after permission for autopsy from relatives. LAAs, RAAs, and samples of
the left and right atrial free wall were gathered from this group. Causes of
death were alcohol abuse (n ¼ 2), cardiogenic shock after acute myocar-
dial infarction (without a cardiac history, n ¼ 1), respiratory failure due
to chronic obstructive pulmonary disease (n ¼ 1), hepatic coma (n ¼ 1),
metastasized small cell lung carcinoma (n ¼ 1), metastasized rectum car-
cinoma (n ¼ 1), sepsis with known non–Hodgkin lymphoma (n ¼ 1),
sepsis eci (n ¼ 1), and cerebrovascular attack (n ¼ 1). There was no doc-
umentation or suspicion of AF in the medical history of the control
patients.328 The Journal of Thoracic and Cardiovascular SurgCollected Patient Data
Pre-, peri-, and postoperative data were retrospectively collected from
inpatient and outpatient hospital files of the patients who had undergone
a Maze III procedure. These included patient demographics, medication,
echocardiographic data, left- and right-sided pressure, and type of surgery.
Collected patient data entailed age, gender, length, weight, previous
catheter ablations, type of AF, duration of AF, serum creatinine, history
of diabetes mellitus, and blood pressure. The last 3 blood pressure record-
ings before surgery were noted. AF was classified as paroxysmal, persis-
tent, or permanent. We deviated from the Heart Rhythm Society’s
consensus article12 because this consensus was not available at the time
of operation.
The use of angiotensin inhibitors, statins, aldosterone antagonists, and
antihypertensive drugs during the last 3 months before operation and amio-
darone use anytime before operation were noted.
Echocardiographic data consisted of the left atrial diameter (long para-
sternal axis), right atrial diameter (long axis in 4-chamber view), left ven-
tricular end-diastolic/systolic diameter, and left ventricular ejection
fraction. From the catheterization records, we obtained wedge pressure;
right atrial pressure; left ventricular systolic and diastolic pressures; right
ventricular systolic pressure; and diastolic, systolic, and mean pulmonary
artery pressures.
Histology
Tissue samples were fixed in 4% buffered formalin immediately after
excision. After fixation, tissues were embedded in paraffin, and 4-mm trans-
versal sections at the base of the appendages were cut and stained with pic-
rosirius red for visualization and quantification of collagen in the fibrous
tissue.
Four digital pictures were taken with a 103 objective at 3, 6, 9, and 12
o’clock of the tissue sections. Background, perivascular, endocardial fibro-
sis, and epicardial fibrosis were excluded by manually revising every pic-
ture with Adobe Photoshop 9.0 (Adobe Systems Inc, San Jose, Calif)
(Figure 1). Thereafter, the amount of fibrous tissue was calculated by quan-
titative spectrometry with Image-pro 6.2 (Media Cybernetics Inc, Be-
thesda, Md). The percentage of fibrous tissue was expressed as the
amount of red (collagen) relative to the total amount of tissue (perivascular,
endocardial, and epicardial fibrous tissue excluded). A total of 1048 pic-
tures were taken, revised, and analyzed without any knowledge of the pa-
tient characteristics.ery c August 2012
TABLE 1. Patient characteristics
Lone AF
(n ¼ 85)
AFþMVD
(n ¼ 26)
Controls
(n ¼ 10)
P
value
Age (y) 50.7  8.7 59.0  7.6 62.6  15.7 <.001*
<.001y
.470z
Male gender 88% (75/85) 65% (17/26) 50% (5/10) .016*
.007y
.641z
BSA (m2) 2.11  0.20 1.96  0.23 .003
BMI (kg/m2) 27.5  4.28 24.8  3.93 .005
Diabetes mellitus 2% (2/85) 0% (0/0) .958
GFR
(mL/min/1.72 m2)x
81.4  14.6 72.1  15.6 – .011
AF duration (mo) 91.3  61.3 47.6  47.1 – <.001
Type of AF
Paroxysmal 72% (61/85) 31% (8/26) – <.001
Persistent 20% (17/85) 23% (6/26)
Permanent 8% (7/85) 46% (12/26)
Previous catheter
ablation
15% (13/85) 0% (0/26) – .076
Type of concomitant
cardiac surgery
Mitral valve 0% (0/85) 100% (26/26) – N/A
Tricuspid valve 0% (0/85) 15% (4/26) .002
CABG 0% (0/85) 4% (1/26) .529
ASD (all type II) 7% (6/85) 4% (1/26) .898
Medication use
Amiodarone 62% (53/85) 12% (3/26) – <.001
Antihypertensive
drugs
22% (19/85) 54% (14/26) .013
ACEI 20% (17/85) 54% (14/26) .002
Aldosterone
antagonist
0% (0/0) 8% (2/26) .082
Statin 12% (10/85) 0% (0/0) .149
BSA, Body surface area; BMI, body mass index; GFR, glomerular filtration rate;
CABG, coronary artery bypass grafting; ACEI, angiotensin-converting enzyme inhib-
itor. *Lone AF vs AF þMVD. yLone AF vs controls. zAF þMVD vs controls.
xCalculated GFR.13
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Values are presented as mean standard deviation, percentages stan-
dard deviation, or different when indicated. Continuous variables were
compared with paired Student t, unpaired Student t test, Mann–Whitney
test, or analysis of variance test with post hoc Tukey honestly significant
difference comparison, where appropriate. Categoric variables were com-
pared with the Pearson’s chi-square test with Yates’ continuity correction.
For correlation, the squared Pearson correlation coefficient was computed
along with a scatter plot for visual inspection.
The distribution of the percentage fibrosis in the atrial appendages was
skewed to the right and near normal after log-transformation. For the uni-
variate statistics, we used the nontransformed data to keep the original
units. For the multivariate analysis, we used the log-transformed data.
The multivariate analysis consisted of linear regression with log-
transformed percentage fibrosis in the atrial appendage as the dependent
variable. All variables with P<.1 in a bivariate analysis were candidate in-
dependent variables for the multivariate regression. We used generalized
linear modeling, and the best multivariate model emerged after ranking
of all possible models by the Akaike’s information criterion, which is
a measure of the goodness of fit of an estimated statistical model.
For the repeated-measurements analysis involving right- and left-sided
atrial fibrosis as separate values in 1 patient, we used a generalized linear
mixed-effects modeling with fibrosis as the dependent variable and individ-
ual as random intercept, disease with 3 categories (AFþMVD, lone AF,
and control), left or right side, and the natural logarithm of fibrosis as in-
dependent variables. All statistical calculations were performed with R
software (http://www.r-project.org).
RESULTS
Patient Characteristics
Table 1 shows patient characteristics, type of surgery, and
medication use for the lone AF and AFþMVD groups. The
echocardiographic and hemodynamic data are presented in
Table 2, showing as expected, that the AFþMVD group had
generally larger atrial and ventricular dimensions and
higher pressures than the lone AF group.
Atrial Interstitial Fibrosis
Figure 2 depicts the amount of fibrous tissue in the LAA
and RAA for the different groups. The mean amount of fi-
brous tissue in the atria (LAA and RAA combined) differs
significantly among the AFþMVD, lone AF, and control
groups (13.6%  5.8%, 9.7%  3.2%, and 8.8% 
2.4%, respectively, P<.01). By using a generalized linear
mixed-effects model, the following pattern emerges: The
right atrium contains 1.5 times more fibrosis (P< .001)
than the left atrium. The atria of the AF þ MVD group
have 1.4 times more fibrosis than the control group
(P¼ .01) and 1.3 times more fibrosis than the lone AF group
(P ¼ .01). No significant difference exists between the
amount of atrial fibrosis in the lone AF and control groups.
The amount of fibrous tissue in the appendages of the con-
trol group did not significantly differ from that in the free
wall of the atria (RAA ¼ 10.2%  4.0%, right atrial free
wall ¼ 12.6%  5.4%, P ¼ .3; LAA ¼ 7.5%  2.2%,
left atrial free wall ¼ 7.3%  1.9%, P ¼ .8).
The amount of fibrous tissue in the RAA and LAA corre-
lated significantly to each other (r ¼ 0.49, P<.0001).The Journal of Thoracic and CaPredictors for Atrial Interstitial Fibrosis
Table 3 shows the univariate analysis of different vari-
ables for the amount of fibrous tissue in the LAA and
RAA. The amount of fibrous tissue correlates positively
with left and right atrial diameter, left ventricular end-
diastolic diameter, right ventricular systolic pressure, pul-
monary artery pressures, surgery for MVD, and surgery
for tricuspid valve disease, but negatively with statin use.
Figure 3 depicts scatter plots of continuous variables that
significantly correlated to the amount of fibrous tissue in the
LAA or RAA. Subsequent multivariate analysis showed
that the following factors were independently associated
with an increased amount of fibrous tissue in the LAA or
RAA: surgery for tricuspid valve disease (factor 1.8,
P ¼ .04), right atrial diameter (factor 1.02/mm, P<.01),
and surgery for MVD (factor 1.3, P< .01). A protectiverdiovascular Surgery c Volume 144, Number 2 329
TABLE 2. Echocardiographic data, blood pressure, and right-sided
catheterization pressures
Lone AF
(n ¼ 85)
AFþMVD
(n ¼ 26)
Controls
(n ¼ 10) P value
Left atrial ø (mm) 42.3  7.1 53.7  9.0 – <.001
Right atrial ø (mm) 53.5  5.6 59.9  11.5 – .021
LVEDD (mm) 50.2  5.6 58.8  9.8 – <.001
LVESD (mm) 35.4  5.2 43.0  8.4 – <.001
LVEF
>50% 94% (80/85) 81% (21/26) – .097
40%–50% 4% (3/85) 15% (4/26)
30–40% 2% (2/85) 4% (1/26)
Blood pressure
(mm Hg)
–
Systolic 135  17 133  19 .695
Diastolic 83  9 79  8 .028
Mean 100  11 97  11 .182
Catheterization
pressures (mm Hg)
–
Right atrium mean 4.6  2.9 5.3  4.0 .454
Wedge 9.4  3.9 19.9  8.0 <.001
RV systolic 25.7  6.2 48.7  25.6 .001
LV end systolic 130  22 131  29 .940
LV end diastolic 10.4  4.9 13.3  6.4 .063
Systolic PAP 25.1  6.6 45.0  15.8 <.001
Diastolic PAP 9.3  4.1 19.0  9.0 <.001
Mean PAP 15.6  4.9 27.3  10.7 <.001
ø, Diameter; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular
end-systolic diameter; LVEF, left ventricular ejection fraction; RV, right ventricle; LV,
left ventricle; PAP, pulmonary artery pressure.
FIGURE 2. Amount of fibrous tissue in LAA and RAA per group. Peri-
vascular, endocardial fibrosis, and epicardial fibrosis were excluded. Values
are given as percentage with the standard error of the mean (error bars).
*P< .05. LAA, Left atrial appendage; RAA, right atrial appendage; AF,
atrial fibrillation; MVD, mitral valve disease.
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crease of fibrous tissue of 0.76 (P ¼ .06).
For the average amount of fibrosis (RAA and LAA com-
bined), surgery for MVDwas the only remaining significant
predictor. Patients with surgery for MVD had a 1.7 esti-
mated increase of fibrous tissue (P<.01).
DISCUSSION
It is well recognized that fibrous tissue can play an impor-
tant role in the pathogenesis of AF.2-5 On the other hand, AF
itself may result in fibrosis.2 The main finding of this study
is that patients with AF and MVD have more atrial fibrosis
than patients with lone AF. Furthermore, no difference in
atrial fibrosis was found between patients with lone AF
and controls. This suggests that AF itself does not result
in fibrosis in patients with lone AF and that the mechanism
of the arrhythmia in these patients is more likely to be re-
lated to electrical or autonomic remodeling. This is further
endorsed by the multivariate analysis, which found no rela-
tion between fibrosis and duration of AF; however, we can-
not exclude that structural changes different from fibrosis
play a role in lone AF.
In our study, the amount of fibrous tissue in the LAA and
RAA did not significantly differ from that of the corre-
sponding left and right atrial free wall. Our findings in the330 The Journal of Thoracic and Cardiovascular Surgatrial appendages may therefore be extrapolated to the atrial
free wall.
This study also showed that the right atrium contains
more fibrous tissue than the left atrium. This finding is con-
cordant with the results of Oken and Boucek,14 who showed
that both the right ventricle and the atrium contain more fi-
brous tissue than the left ventricle and atrium. We speculate
that the difference in the amount of fibrous tissue between
the right and the left atrium has a developmental origin.
First, the right atrium has a different embryonic identity
than the left atrium.15 Second, the pressures of the right
side of the heart are higher than the left side during fetal
circulation.16
This study showed a trend toward a negative correlation
between statins and atrial fibrosis. The protective role of sta-
tins in the prevention of AF has been recognized, but the ex-
act pathophysiology of its protective role is unknown.17,18
Fibrosis has been suggested to play a role in this matter.19
To our knowledge, this is the first study to describe a nega-
tive relation between statin use and amount of atrial intersti-
tial fibrosis.
Substrate and Trigger
This study showed that patients with AF and MVD have
more interstitial fibrosis than patients with lone AF. This is
probably the explanation for the relatively low success rate
of antiarrhythmic surgery in patients with AF andMVD, es-
pecially when only a pulmonary vein isolation is per-
formed.7 The greater amount of fibrosis in patients withery c August 2012
TABLE 3. Univariate analysis for the fibrous content in both atria
(pooled)
Predictors of fibrosis
Estimate
(log)
CI
lower
CI
upper Missing
P
values
Age 0.002 0.006 0.010 0 .6798
Male gender 0.174 0.368 0.020 0 .0779
BSA 0.175 0.520 0.170 1 .3165
BMI 0.010 0.027 0.007 1 .2435
Diabetes mellitus 0.077 0.480 0.633 0 .7855
GFR 0.003 0.002 0.007 0 .3084
AF duration* 0.039 0.112 0.189 2 .6107
Type AFy 0.130 0.020 0.281 0 .0896
Previous catheter
ablationz
0.044 0.186 0.274 0 .7053
Left atrial ø 0.009 0.001 0.017 1 .0338
Right atrial ø 0.016 0.006 0.026 12 .0014
LVEDD 0.012 0.002 0.022 9 .0224
LVFx 0.046 0.141 0.232 0 .6280
Blood pressure, systolic 0.001 0.005 0.003 0 .6723
Blood pressure, diastolic 0.007 0.016 0.001 0 .1032
Blood pressure, mean 0.004 0.011 0.003 0 .2746
Right atrium pressure 0.004 0.025 0.033 26 .7734
Wedge pressure 0.008 0.004 0.021 22 .1960
RV systolic pressure 0.005 0.000 0.010 31 .0427
LV end–systolic pressure 0.001 0.002 0.005 11 .5202
LV end–diastolic pressure 0.007 0.009 0.023 19 .3862
PAP systolic 0.008 0.002 0.015 20 .0127
PAP diastolic 0.007 0.005 0.020 20 .2285
PAP mean 0.013 0.002 0.024 28 .0184
Amiodarone 0.118 0.265 0.028 0 .1116
Antihypertensive drugs 0.129 0.033 0.290 0 .1170
ACEI 0.087 0.077 0.251 0 0.2949
Aldosterone antagonist 0.136 0.692 0.420 0 .6298
Statin 0.264 0.517 0.010 0 .0419
Mitral valve surgery 0.299 0.134 0.464 0 .0005
Tricuspid valve surgery 0.419 0.030 0.808 0 .0351
ASD type II closure 0.044 0.349 0.260 0 .7727
Estimate denotes beta regression parameter as a measure of association. Values in
bold text were applicable for multivariate analysis (P<.1). ø, Diameter; LVEDD,
left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter;
LVEF, left ventricular ejection fraction; RV, right ventricle; LV, left ventricle; CI, con-
fidence interval; PAP, pulmonary artery pressure. *History of AF<5 vs>5 years.
yParoxysmal versus continuous (persistent and permanent) AF. zEither pulmonary
vein isolation or right-sided isthmus ablation in history. xDivided into groups of an
ejection fraction of>50%, 40%–50%, or 30%–40%.
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have relatively more persistent and permanent AF than pa-
tients with lone AF, despite their shorter history of AF
(Table 1).
The increased amount of fibrous tissue in the atria of pa-
tients with AF secondary to MVDmight be due to increased
wall stress.6,20 The wall stress is dependent on both the
pressure and diameter of the atrium (Laplace’s law), and
these were both significantly larger in the AF þ MVD
group compared with the lone AF group. However,
increased fibrosis in patients with AF secondary to MVD
also may be due to heart failure.21 The AFþMVD groupThe Journal of Thoracic and Cahad larger left ventricular dimensions and an impaired glo-
merular filtration rate, which suggests at least some systolic
heart failure.
Age and Fibrosis
Because the mean age of patients with AFþMVD ex-
ceeded that of patients with lone AF, one could argue that
differences in atrial fibrosis between the groups rely on
age differences. However, the multivariate analysis showed
that MVD is associated with a 72% increase in atrial fibro-
sis (P<.01) and that age was not related to the amount of
fibrosis (P ¼ .7). Even when we limit the analysis to the 5
youngest patients of the control group (aged 50.4  11.2
years), there is no significant difference in the amount of fi-
brous tissue between the control and lone AF groups (aged
50.7  8.7 years).
Evidence for age-related human atrial fibrosis is scarce
and conflicting. Although 2 studies have found a relation
between age and atrial fibrosis,22,23 others have not.15,21
The relation between age and fibrosis in these studies
could be attributed to the increased prevalence of other
cardiovascular diseases in elderly people, such as
hypertension, coronary artery disease, heart failure, and
cardiac valve pathology. Furthermore, it could be that the
distribution of age (52  9 years) in this study was too
small to find an increase of fibrosis with age, which is
often the case in animal studies.
Fibrosis and Atrial Fibrillation
Recent magnetic resonance imaging studies showed that
the success after a percutaneous vascular intervention de-
pends on the late enhancement of the left atrial wall,
which correlates to the amount of fibrous tissue.24 Our
study showed that the right atrium contains more fibrous
tissue than the left atrium. This underscores the impor-
tance of inclusion of the right atrium in the surgical treat-
ment of AF, especially in patients with MVD. The Maze
III operation modifies the substrate in both atria and is still
considered as the golden standard for nonpharmacologic
treatment of AF with a reported long-term success of
more than 90%.7,11
Limitations
Because of the small wall thickness of the atria, we were
unable to make parallel sections and could not discriminate
among patchy, diffuse, and compact fibrosis. These differ-
ent types of fibrosis have different electrophysiologic ef-
fects.10 However, no compact fibrosis was encountered in
the transverse sections.
This study shows no increase in fibrous tissue for patients
with lone AF compared with controls. We cannot exclude
that a different geometry of the fibrous tissue or other types
of structural remodeling (eg, Cx43 expression) play a role in
these patients.rdiovascular Surgery c Volume 144, Number 2 331
FIGURE 3. Scatter plots of different continuous variables in relation with the amount of interstitial fibrosis in the LAA or RAA. Other continuous variables
that correlated significantly with the amount of fibrosis, but not displayed, are as follows: LVEDD: RAA; r ¼ 0.21, P ¼ .03, LAA; r¼ 0.28, P<.01. Right
ventricular systolic pressure: RAA; r¼ 0.27, P¼ .02, LAA; r¼ 0.34, P<.01. Systolic pulmonary artery pressure: RAA; r¼ 0.25, P¼ .02, LAA; r¼ 0.30,
P<.01. LAA, Left atrial appendage; RAA, right atrial appendage.
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isted between the groups because of selection of the patient
population. Meticulous analysis showed no relation be-
tween age and fibrosis, but we cannot exclude that unre-
corded differences in baseline characteristics interfered
with our results.
The amount of fibrous tissue in the lone AF and AFþ
MVD groups was determined at the base of the atrial ap-
pendages and not in the atria itself. Although no difference
existed in the control group, a discrepancy in the amount of
fibrous tissue between the appendages and atria could exist
in these 2 groups.
CONCLUSIONS
The atria of patients with AF secondary to or in com-
bination with MVD contain more fibrous tissue than atria332 The Journal of Thoracic and Cardiovascular Surgof patients with lone AF, whereas atria of patients with
lone AF have an equal amount of fibrous tissue as con-
trols. In general, the right atrium contains more fibrous
tissue than the left atrium. These findings suggest that
AF secondary to or in combination with MVD is depen-
dent on atrial interstitial fibrosis, whereas lone AF is more
dependent on electrical or autonomic remodeling. This
suggests that for treatment of AF secondary to MVD,
a different percutaneous or surgical approach should be
applied than in lone AF. Furthermore, statins may reduce
the amount of fibrous tissue in the atria and are therefore
of interest in pharmacologic therapy for the prevention
of AF.
The authors thank P.C. de Bruin of the Pathology Department
for work that made this article possible.ery c August 2012
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